DDB2 and ovarian cancer: Notably, DDB2 knockdown (+Dox) enhanced the tumorigenic potential of those CD44−CD117− cells after 12 days of culture (Fig. 1f, middle panel), further supporting the role of DDB2 silencing in promoting non-CSC-to-CSC conversions in this ovarian cancer cell line.